Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PRT3789 in advanced or metastatic SMARCA4-mutant solid tumors
NL-OMON58989Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Mar 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRT3789 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC) and 13 more, sponsored by Prelude Therapeutics. Primary endpoint: Primary endpoint(s). Started Mar 2024; status: completed.
02
Drugs
PRT3789
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)Pulmonary squamous cell carcinomamelanoma
Beyond the preview
Go deeper on NL-OMON58989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58989.